Ertugliflozin, Renoprotection and Potential Confounding by Muscle Wasting
Overview
Overview
Authors
Affiliations
Affiliations
Soon will be listed here.
Citing Articles
Muscle mass and estimates of renal function: a longitudinal cohort study.
Groothof D, Post A, Polinder-Bos H, Erler N, Flores-Guerrero J, Kootstra-Ros J J Cachexia Sarcopenia Muscle. 2022; 13(4):2031-2043.
PMID: 35596604 PMC: 9398222. DOI: 10.1002/jcsm.12969.
Cherney D, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire D, Pratley R Diabetologia. 2022; 65(5):908-911.
PMID: 35238955 PMC: 8960556. DOI: 10.1007/s00125-021-05623-z.
References
1.
Cherney D, Charbonnel B, Cosentino F, Dagogo-Jack S, McGuire D, Pratley R
. Effects of ertugliflozin on kidney composite outcomes, renal function and albuminuria in patients with type 2 diabetes mellitus: an analysis from the randomised VERTIS CV trial. Diabetologia. 2021; 64(6):1256-1267.
PMC: 8099851.
DOI: 10.1007/s00125-021-05407-5.
View
2.
Levey A, Inker L, Matsushita K, Greene T, Willis K, Lewis E
. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014; 64(6):821-35.
DOI: 10.1053/j.ajkd.2014.07.030.
View
3.
Post A, Eisenga M, Bakker S
. Canagliflozin and Renal Outcomes in Diabetic Nephropathy. N Engl J Med. 2019; 381(11):1089.
DOI: 10.1056/NEJMc1909687.
View
4.
Marton A, Kaneko T, Kovalik J, Yasui A, Nishiyama A, Kitada K
. Organ protection by SGLT2 inhibitors: role of metabolic energy and water conservation. Nat Rev Nephrol. 2020; 17(1):65-77.
DOI: 10.1038/s41581-020-00350-x.
View
5.
Cherney D, Perkins B, Soleymanlou N, Maione M, Lai V, Lee A
. Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus. Circulation. 2013; 129(5):587-97.
DOI: 10.1161/CIRCULATIONAHA.113.005081.
View